The pooled assessment outcomes for 6 studies were as follows: sensitivity, 0.83 (95% CI= 0.80-0.86); specificity, 0.83 (95% CI=0.80-0.86); DOR, 0.83 (95% CI=0.80-0.86); and area under the curve (AUC), 0.83 (95% CI=0.80-0.86), indicating a high diagnostic accuracy of urinary UCA1 for bladder cancer. This evidence concerns the gene UCA1 and urinary bladder cancer.